The Veterinary Resources Support Facility is operated out of the Department of Veterinary Sciences, a component of the M.D. Anderson Science Park. This CCSG-support CORE facility provides a cost-effective, Cancer Center-wide Rodent Serology Program that supports the health of rodent research colonies and the operation of SPF facilities throughout the institution, where utilization approaches 100,000 rodents per year. At the Science Park campus, serology and other forms of health and genetic assessment comprise the Rodent Health and Genetic Quality Assurance Program, integral to maintenance of 14,500 SPF rodents and the numerous inbred and transgenic breeding production colonies maintained at that campus. These programs provide animal health information that is vital to the utilization of defined animal models that are free of intercurrent disease or silent infections. These goals are particularly critical for complex cancer models in areas such as carcinogenesis, chemoprevention, and gene-, immuno-, biological-, and radio-therapy. The Veterinary Resources Support Facility also provides a clinical veterinarian (65%) that oversees the rodent facilities at both Science Park campuses, provides specialized research services, managed breeding production colonies, and assists MDACC investigators with custom polyclonal antisera production (cost recovered). We are requesting new funds to provide investigators with assistance in transgenic breeding management and PCR sample collection as part of the services of producing transgenic animals. An electronic communique for institutional transgenic users and mechanisms for re-deriving imported transgenics harboring pathogens will also be established.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-24S1
Application #
6314538
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Li, Jialu; Fu, Chunxiao; Speed, Terence P et al. (2018) Accurate RNA Sequencing From Formalin-Fixed Cancer Tissue To Represent High-Quality Transcriptome From Frozen Tissue. JCO Precis Oncol 2018:
Fujii, Takeo; Colen, Rivka R; Bilen, Mehmet Asim et al. (2018) Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36:638-646
Hoover, Diana Stewart; Wetter, David W; Vidrine, Damon J et al. (2018) Enhancing Smoking Risk Communications: The Influence of Health Literacy and Message Content. Ann Behav Med 52:204-215
Franco, Hector L; Nagari, Anusha; Malladi, Venkat S et al. (2018) Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res 28:159-170
Altok, Muammer; Achim, Mary F; Matin, Surena F et al. (2018) A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol 36:13.e19-13.e25
Patel, Sameer H; Kim, Bradford J; Tzeng, Ching-Wei D et al. (2018) Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients. J Gastrointest Surg 22:467-476
Assi, Rita; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol 25:136-145
Viswanath, Pavitra; Peng, Shaohua; Singh, Ratnakar et al. (2018) A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. Neoplasia 20:975-984
Ma, Grace X; Lee, Minsun M; Tan, Yin et al. (2018) Efficacy of a community-based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans. Cancer 124:973-982
Peng, Guang; Mills, Gordon B (2018) Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1. Clin Cancer Res 24:508-510

Showing the most recent 10 out of 12418 publications